Objective: Randomized trials support carotid endarterectomy (CEA) in asymptomatic patients with $60% internal carotid artery (ICA) stenosis. The widely referenced Society for Radiologists in Ultrasound Consensus Statement on carotid duplex ultrasound (CDUS) imaging indicates that an ICA peak systolic velocity (PSV) $230 cm/s corresponds to a $70% ICA stenosis, leading to the potential conclusion that asymptomatic patients with an ICA PSV $230 cm/s would benefit from CEA. Our goal was to determine the natural history stroke risk of asymptomatic patients who might have undergone CEA based on consensus statement PSV of $230 cm/s but instead were treated medically based on more conservative CDUS imaging criteria.
Stroke is the fourth-leading cause of death among United States citizens and represents a substantial burden on the health care economic system. 1 As a major risk factor for stroke, carotid artery stenosis is estimated to affect nearly 12% of Americans aged >70 years. 2 In an effort to combat this problem and decrease stroke risk, a substantial amount of time and resource allocation has been devoted toward determining the most appropriate threshold for revascularization. [3] [4] [5] As a consequence, carotid endarterectomy (CEA) has emerged as one of the most common operations performed by vascular surgeons in contemporary practice. Furthermore, with the advent of carotid artery stenting (CAS), nonsurgical specialties have also begun to treat carotid disease, leading to a rapid rise in the number of patients who undergo revascularization. 6, 7 Although there is little debate whether to treat those with symptomatic stenosis, the optimal management of asymptomatic patients has been called into question, 8, 9 because approximately two-thirds of revascularization procedures performed in the United States are for asymptomatic disease. 6 Despite level 1 evidence demonstrating the benefit of CEA vs medical therapy in asymptomatic patients, 4 ,10,11 some
From the Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon a investigators have suggested that medical therapy has improved to a point that trial results no longer apply. 8 Conversely, additional published reports suggest there is a subset of patients at high risk for inferior outcomes with medical therapy, despite an asymptomatic status. 9, 12 To compound the problem of clarifying the natural history of asymptomatic carotid disease, no standard carotid duplex ultrasound (CDUS) criteria exist to guide duplex classification of disease severity. Randomized trials support CEA in asymptomatic patients with a $60% stenosis, however the most appropriate CDUS thresholds to determine this level of disease remain unknown. [13] [14] [15] [16] [17] The widely referenced Society for Radiologists in Ultrasound Consensus Statement on CDUS criteria has indicated that an internal carotid artery (ICA) peak systolic velocity (PSV) of $230 cm/s be used as the criterion to establish $70% stenosis. 18 However, as previously demonstrated by Arous et al, 19 substantial variation exists in institutional protocols for determining the degree of stenosis and, presumably, the threshold for intervention. This ambiguity has a potential effect not only on patient outcomes but almost certainly also on health care costs. 20 Our institution has a long-standing interest in CDUS validation 21 and has developed stringent, internally validated, criteria for the degree of stenosis based on the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method. 22 Our CDUS criteria for $80% stenosis are ICA PSV $430 cm/s, end-diastolic velocity $151 cm/s, and ICA-to-common carotid artery ratio $7.5. Compared with other published criteria, these thresholds are relatively high, 19 and therefore, a significant portion of our patients enter surveillance. The purpose of this study is to report the natural history of patients with asymptomatic carotid disease who were managed using these conservative CDUS criteria. In addition, we propose to determine the fraction of strokes in this population that are potentially preventable by prophylaxis with CEA or CAS.
METHODS
This study was conducted in compliance with the Committee for the Protection of Human Subjects at the Geisel School of Medicine at Dartmouth. All patient personal health information was protected, records and outcomes were deidentified, and no testing or procedures were required for this study. Thus, the need for specific consent was waived.
Data collection and patient identification. All patients who underwent CDUS imaging from January 1, 2009, to December 31, 2009 , were retrospectively identified using a prospectively maintained vascular laboratory database. The year 2009 was chosen to ensure adequate follow-up (mean follow-up, 4.3 years). Patient demographics and comorbidities were collected. Comorbidities were defined as having a documented diagnosis on history and physical examination at the time of the index CDUS study. Surveillance CDUS studies were examined for standard velocity criteria, change in velocities over time, and presence of a previous CEA, CAS, or occlusion. Medical and surgical management were noted. If the patient appeared to be lost to follow-up, contact by telephone of the patient or his or her primary care physician was attempted.
The Dartmouth-Hitchcock vascular laboratory duplex velocity criteria for percentage stenosis have been standardized against conventional carotid angiography (Fig 1) . 4, 21, 22 All CDUS criteria undergo annual validation for accuracy by a senior registered vascular technician and senior vascular surgeon. Further detail about our institutions CDUS protocol can be found in the Appendix (online only).
Inclusion and exclusion criteria. Patients were eligible for inclusion if they had at least one asymptomatic carotid artery under surveillance that had not previously undergone an intervention with CEA or CAS. Patients were considered asymptomatic according to the definition set by the Asymptomatic Carotid Surgery Trial 3 and the Asymptomatic Carotid Atherosclerosis Study. 4 We chose ICA PSV $230 cm/s as the minimum velocity for inclusion based on the Society for Radiologists in Ultrasound Consensus Statement criterion for $70% stenosis. 18 We excluded 29 patients who met the criteria for $80% stenosis at our own institution. Recommendation: These data suggest that future prospective randomized trials for management of asymptomatic carotid stenosis should address the optimal ultrasound thresholds for interventions. dissection). Presence of a contralateral $80% stenosis was noted and included as a baseline characteristic for analysis.
End points and definitions. Study end points included freedom from progression to transient ischemic attack (TIA), freedom from any stroke, freedom from carotidetiology stroke, and freedom from revascularization. TIA was defined as progression to ipsilateral neurologic symptoms, with no evidence of stroke on magnetic resonance imaging, or by resolution of symptoms #24 hours if no magnetic resonance imaging was available. Critical ($80%) stenosis was defined as having any of the velocity criteria shown in Fig 1 because this is our institutional standard. Carotidetiology stroke was defined as a stroke event that was determined to be due to the ipsilateral carotid artery after independent blinded review of all neurologic events by a board-certified vascular surgeon and stroke neurologist. Stroke events that were felt to be of carotid origin by either specialty were included for this end point.
Statistical analysis. Patients were only allowed to contribute one artery to the analysis. Bilateral asymptomatic disease was noted and included as a baseline characteristic. Bilateral asymptomatic stenosis meeting criteria for review was found in 28 patients (9% of patients), and the carotid chosen for analysis was determined at random. Kaplan-Meier analysis was used to determine freedom from TIA, any stroke, carotid-etiology stroke, and revascularization. Life tables were created for all outcomes. A sensitivity analysis was conducted to ensure that the random selection of a single carotid in patients with bilateral disease did not provide dissimilar results. Life tables comparing all eligible carotid arteries to randomly selected carotids in bilateral disease cases showed no significant difference in outcomes. Patients were censored from clinical event life tables at revascularization, loss to follow-up, or death. Patients were censored from revascularization at loss to follow-up or death. Survival curves were truncated at 5 years and thus do not show a small number of events occurring after that time. Cox proportional hazard modeling was performed to determine factors associated with progression to symptoms, stroke, and revascularization. Statistical analyses were performed using Stata software (StataCorp LP, College Station, Tex).
RESULTS
Cohort characteristics. During the study interval, 426 patients met the inclusion criteria. Symptomatic status or severe stenosis ($80% by local duplex criteria) at presentation was present in 99 patients, leaving 327 patients for analysis. The mean age at the time of the index study was 73 years (standard deviation, 8.5 years), and 51% were male. The majority were receiving antiplatelet (94%) or statin (80%) therapy. Comorbid conditions and risk factors were typical for this patient population (Table I) . Mean follow-up was 4.3 years.
Clinical outcomes. Progression to TIA occurred in 17 patients (Table II) Contralateral occlusion 20 (6) Contralateral revascularization 59 (18) Patients with 2 eligible carotids 28 (9) CKD, Chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; SD, standard deviation. a Categoric data are shown as number (%) and continuous data as indicated.
96% and 95% at 1, 3, and 5 years, respectively (Fig 2) . Revascularization was undertaken in 12 TIA patients (12 CEA and 0 CAS), and five were managed medically because of patient preference or severe comorbid illness. No strokes (carotid-etiology or other) occurred in patients who progressed to TIA, including those managed medically. Unheralded stroke occurred in 16 patients, with actuarial freedom from any stroke of 99%, 96%, and 93% at 1, 3, and 5 years (Fig 3) . Twelve of these stroke events (75%) were not attributable to the ipsilateral carotid artery after independent adjudication by a vascular surgeon and stroke neurologist. The 12 strokes were managed medically. The ipsilateral carotid artery was the most likely culprit lesion in four stroke events, with freedom from carotid-etiology stroke of 99.7%, 98.4%, and 98.4% at 1, 3, and 5 years (Fig 4) . Of the four patients who sustained a carotid-etiology stroke, one underwent CEA and the remaining three were managed medically at the patient's request (Table III) . When stratified by level of stenosis found on the index CDUS study, no association was found between the level of stenosis (50%-59%, 60%-69%, and 70%-79%) for TIA (P ¼ .18), carotid-etiology stroke (P ¼ .84), or any stroke (P ¼ .81). CEA was undertaken in 56 patients and CAS in three patients, with a total freedom from revascularization of 95%, 86%, and 81% at 1, 3, and 5 years (Fig 5) . The indication for revascularization was progression to $80% stenosis by local duplex criteria in 33 patients, 70% to 79% stenosis in 13, TIA in 12, and stroke in 1. Overall survival at 5 years was 75% among all patients.
Predictive variables. Individual Cox proportional hazard models were created to determine factors associated with the primary end points. Progression to TIA was associated with an increase in the ICA PSV to $430 cm/s (hazard ratio [HR], 3.8; 95% confidence interval [CI], 1.3-11; P ¼ .02) as well as a baseline ICA PSV of >302 cm/s (HR, 3; 95% CI, 1.04-8.5; P ¼ .04). Too few carotid-etiology stroke events occurred to create a meaningful model predictive of this outcome. However, hazard modeling found an association with any-cause stroke for congestive heart failure (HR, 4.4; 95% CI, 1.3-15; P ¼ .02) and prior contralateral CEA (HR, 4.2, 95% CI, 1.4-13; P ¼ .01). As expected, progression to severe stenosis by duplex criteria was associated with revascularization, whereas low baseline end-diastolic velocity was protective. Prior contralateral neurologic symptoms #6 months was associated with all-cause mortality (HR, 3.6; 95% CI, 1.2-10.8; P ¼ .02). Additional comorbidities, including hemodialysis, congestive heart failure, chronic pulmonary disease, or diabetes, were also associated with death (Table IV) . (ICA PSV 230-429 cm/s) using conservative CDUS criteria. These individuals are at risk for stroke; however, it is the minority of these strokes that are attributable to the ipsilateral carotid artery. In this cohort, only one-quarter (4 of 16) of stroke events were felt to be of carotid etiology and therefore could have been prevented by CEA or CAS. This is consistent with published reports demonstrating that carotid stenosis causes w25% to 30% of ischemic strokes. 23 Although level 1 data support CEA for arteries with $60% stenosis, 4,10 the use of the consensus criteria of an ICA PSV $230 cm/s correlating to $70% stenosis would have led to a large number CEAs in patients who could have otherwise been safely treated with medical therapy and close surveillance. 18 Clinical trial data support CEA for patients with asymptomatic carotid stenosis $60%. 3, 4 Despite this, some have postulated that these data are no longer relevant, under the presupposition that medical therapy has advanced to the point that revascularization should only be considered for arteries with $80% stenosis, or perhaps not at all. Evidence has arisen on both sides of this debate. 24, 25 For example, Conrad et al 9 documented a rate of progression to ipsilateral neurologic symptoms of 25% in a cohort of 126 patients with asymptomatic severe stenosis at a mean follow-up of 27 months, 14 of whom presented as unheralded strokes. Conversely, Abbott has conjectured that "medical therapy alone" is now sufficient to treat asymptomatic patients with 50% to 75% stenosis, citing a number of observational and clinical trials. 8, [26] [27] [28] Although the widespread adoption of statin therapy has likely affected the natural history of patients with peripheral vascular disease, the recent publication of the Asymptomatic Carotid Trial and 10-year Carotid Revascularization Endarterectomy vs Stenting Trial (CREST) trial data has demonstrated that excellent results can be obtained after revascularization. 29, 30 Despite the innumerable opinions that have arisen, there is undoubtedly a subset of patients who will derive benefit from revascularization. 3, 4, 31, 32 Therefore, clearly delineating this group by eliciting the most appropriate duplex velocity threshold for intervention is vital. 33 The decision to undertake carotid revascularization for asymptomatic patients is frequently predicated on the percentage of stenosis based on duplex velocity criteria. Counterintuitively, though, the way in which the percentage of stenosis is determined is widely variable and inconsistent. 19, 20, [34] [35] [36] More than three decades ago, Strandness et al 37 first established a set of CDUS velocity criteria for use in clinical practice. These criteria were widely accepted as an alternative to the previous mechanism of invasive angiography. Since its inception, CDUS velocity criteria have undergone a multitude of permutations in an attempt to advance its use in clinical practice. 14, 19, [38] [39] [40] Although well intentioned, these permutations have had the undesired result of wide variation between centers. This was clearly documented by Arous et al, 19 and has led to an environment where, based on local CDUS criteria, a patient may be offered revascularization at one institution or enter surveillance at another only 10 to 20 miles apart. In this series, we document that among a cohort of patients with an index ICA PSV of 230 to 429 cm/s with a high rate of antiplatelet and statin use, the actuarial freedom from any stroke is 93% at 5 years (Fig 3) . Moreover, only 25% of these strokes would have potentially been prevented by CEA or CAS, with freedom from carotid-etiology stroke rate of 98.4% at 5 years (Fig 4) . These rates approach that of randomized trials reporting midterm and long-term outcomes after intervention for asymptomatic stenosis. 29, 30 Although it is undesirable that 5% (17 of 327) of patients experienced a TIA while under surveillance, as a result of surgical or medical management, no strokes occurred. These findings suggest that it is safe to use conservative CDUS velocity criteria as a threshold for surgical intervention in asymptomatic patients. As may be expected, a history of contralateral CEA was associated with a higher risk of stroke and highlights the nature of the aggressive disease pattern in patients who require revascularization. Congestive heart failure was predictive of stroke, as is consistent with published literature. 41, 42 In addition, progression by duplex and higher baseline velocities were associated with a higher risk of TIA and revascularization. One might speculate that more frequent surveillance, more aggressive medical management, or even CEA/CAS might be useful in this patient cohort, but we cannot answer that question with the current analysis. However, those with asymptomatic carotid stenosis do have an increased risk of all types of stroke compared with the general population, and because of this, intensive medical therapy should be instituted for all patients. Carotid-etiology stroke events represented the minority of events that occurred under surveillance, but these events are of course central to the treatment of carotid stenosis. This level of detail is infrequently reported in clinical trials and is not possible with large data sets because of the inability to determine stroke laterality and differentiate between ischemic and hemorrhagic events. 43, 44 Despite this, it is these specific events that are potentially preventable by surgical revascularization and, therefore, the end point against which CEA and CAS interventional thresholds and outcomes should be adjudicated. Such a level of detail was first described by the NASCET investigators when they reported the natural history of patients who were randomized that were additionally monitored for contralateral asymptomatic stenosis. 45 They elucidated that nearly half of ischemic stroke events that occurred during follow-up in patients with asymptomatic stenosis were lacunar or cardioembolic. They concluded that this would have important implications for patients being considered for revascularization because surgical intervention would likely not reduce the risk of these types of stroke. Indeed, advancements in medical therapy have shown a decrease in overall stroke events over time; however, the distribution of events noted by the NASCET investigators is similar to our findings described here. It is also important to note that 49% of patients included in this analysis would have met the CDUS criteria for inclusion in CREST-2. The baseline characteristics of this subgroup were not statistically different from those of the overall cohort, save for a higher rate of bilateral disease. A subgroup analysis of patients meeting CREST-2 criteria on all of the study outcomes showed survival curves that were nearly identical to those of the entire cohort, and the difference between them was not statistically significant. Historically it may be thought that clinical equipoise exists for patients with intermediate carotid stenosis, but these findings indicate that medical therapy and surveillance is appropriate for many patients with intermediate stenosis by conservative duplex criteria.
DISCUSSION
Moreover, with this low rate of carotid-etiology stroke (and therefore preventable by CEA or CAS), trials using "any stroke" as an end point may be underpowered to detect a benefit for patients undergoing revascularization, biasing results toward noninferiority of medical therapy. 46 Furthermore, if only patients with intermediate carotid stenosis by conservative criteria are randomized to trials, we may soon face level 1 data that no longer support revascularization for asymptomatic carotid stenosis. It is therefore imperative that patients with all grades of asymptomatic disease, including severe stenosis, be randomized, because this subgroup of patients may be most likely to derive a strokeprevention benefit. In summary, the natural history of intermediate asymptomatic carotid stenosis is not benign. However, the incidence of stroke events that occur under surveillance in patients on medical therapy with this level of disease appears to approach that of contemporary revascularization trials. In this cohort, carotid-etiology stroke accounted for only 25% (4 of 16) of events observed in patients under surveillance using our institutional criteria, with freedom from carotid-etiology stroke of 98.4% at 5 years by Kaplan-Meier analysis, a detail unavailable in large data sets. Every effort should therefore be made to extract data on long-term surveillance directly from medical records because this provides the most granular analysis of clinical events outside of randomized trials.
Most of those who progress to symptomatic status should be offered revascularization, as supported by randomized trial results. 5 Asymptomatic progression under surveillance is not unusual, and CEA might be considered for these patients. Baseline velocity criteria and duplex progression are predictive of neurologic events, but the rate of neurologic events is rare, and even the low risk for potential complications with surgical revascularization (ie, stroke, nerve injury) 3, 4, [47] [48] [49] justifies the use of conservative CDUS criteria. This study has intrinsic limitations. First, it is a singlecenter retrospective study. However, because current registries do not include patients who do not undergo intervention or do not provide sufficient detail to parse out the intricacies of each individual stroke, our singlecenter analysis provides a level of granularity that is infrequently available. The included patient population had high compliance with medical therapy and may not extrapolate to all practices.
In addition, it is not possible to know with 100% certainty whether a stroke is preventable by CEA or CAS. However, independent adjudication by a boardcertified vascular surgeon and stroke neurologist allowed for what we believe to be the highest likelihood of correct group assignment. Because not all patients received magnetic resonance imaging, it is possible that some asymptomatic stroke events were not detected.
Lastly, the decision to undertake revascularization was ultimately at the discretion of the attending vascular surgeon, and thus, bias may affect the relatively low rate of elective asymptomatic revascularizations.
CONCLUSIONS
Patients with intermediate asymptomatic carotid artery stenosis by conservative CDUS criteria (ICA PSV 230-429 cm/s) do well with medical therapy when carefully monitored and intervened upon for progression to symptoms or critical stenosis. Although progression of stenosis under surveillance is not uncommon, the unheralded stroke rate is low and comparable to contemporary trials of asymptomatic revascularization. These data suggest that using the consensus criteria correlating a PSV of $230 cm/s with a stenosis of 70% would lead to a large number of CEA or CAS in patients who could have otherwise been safely treated with medical therapy and close surveillance. It is therefore imperative that patients with severe stenosis be randomized to contemporary trials of asymptomatic stenosis, because if only those with intermediate stenosis are included, current trials may be biased to demonstrate no benefit of revascularization. Current recommendations and institutional CDUS velocity criteria should be re-evaluated, and future studies should give careful attention to determining which stroke events could have been prevented by revascularization. Dr Jesse A. Columbo. Patients were offered an intervention at the discretion of the operating surgeon based on local duplex velocity criteria and a discussion of the risks and benefits at the time of the clinic visit.
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Dr Christos Liapis (Athens, Greece). Congratulations. Besides the peak systolic velocity (PSV), did you use anything like plaque characteristics to decide what you were going to do with these patients? Dr Columbo. Plaque characteristics and echogenicity do factor in during the shared decision-making process with the patient. However, as far as percent stenosis and offering an intervention, it is the duplex velocity criteria that usually receive the most weight.
Dr Ali AbuRahma (Charleston, WV). This is a very timely, important presentation, and you have done a good job in presenting the data. However, I would like to suggest that you emphasize, especially for the audience, that when the consensus panel met in 2003, they reviewed over 100 articles and compared various criteria and classifications of stenosis in order to arrive at these numbers. However, they also advised clinicians to validate these data in their own labs, which you have done. Therefore, a PSV of 230 cm/s must be associated with significant plaquing to go along with the >70% stenosis. If you don't see >70% plaquing, you must incorporate other parameters; which you have already touched on, ie, an end-diastolic velocity >100 cm/s and a systolic ratio above 4. Therefore, I am wondering if you should recalculate your data, based not only on a PSV of >230 but also an EDV of 100 cm/s and a systolic ratio of 4 to see if the natural history would be the same. I appreciate your comment.
Dr Columbo. You make a very important point: 49% of our cohort met the criteria that you mention; specifically, a PSV of greater than 230 as well as either an end-diastolic greater than 100 or an internal-to-common carotid ratio of 4. We repeated the analysis on this subgroup of patients; the Kaplan-Meier curves were nearly identical.
Dr Mahmoud Malas (Baltimore, Md). Congratulations on this important and timely study. You clearly showed, similar to our study, that patients with moderate stenosis do not need surgery. In our prior study, only 25% of these patients progressed to severe stenosis, and only 3% became symptomatic. I strongly recommend for everyone who participated in Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST) 2, to randomize all patients, including the patient with severe stenosis. If we only include patients with moderate stenosis, we are going to show that medical management is just as good as carotid endarterectomy in asymptomatic patients. It is our responsibility to also include patients with velocity of 600 and 700 cm/s because this is where we are going to see benefit for intervention over medical management. I wonder if you can comment on that.
Dr Columbo. I think you make an extremely important point. CREST 2 is a very important trial. As you mentioned, if we only enroll patients who are just at the threshold of meeting criteria for inclusion, then the final study analysis may show no benefit to intervention, as these patients likely will fare well with medical therapy. It is very important for us to remember that patients where a benefit is more likely to be found are in those at the upper end of the velocity spectrum. Therefore, it is vital that these individuals be randomized as well.
